Mizuho raised the firm’s price target on Apellis to $60 from $49 and keeps a Neutral rating on the shares. Ahead of Q4 earnings, the firm updated models and revised 12-month price targets in the biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis price target raised to $87 from $70 at UBS
- Biotech Alert: Searches spiking for these stocks today
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis price target raised to $110 from $106 at Raymond James
- Apellis upgraded to Buy from Hold at Jefferies